473
Views
8
CrossRef citations to date
0
Altmetric
Review

Follicular lymphomas and their transformation: Past and current research

, ORCID Icon &
Pages 515-524 | Received 03 Nov 2016, Accepted 02 May 2017, Published online: 16 May 2017

References

  • Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265.
  • Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724.
  • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood. 1997;89:3909.
  • Lorsbach RB, Shay-Seymore D, Moore J, et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood. 2002;99:1959.
  • Louissaint A Jr, Schafemak K, Geyer J, et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathways mutations.
  • Takata K, Tanino M, Ennishi D. Doudenal follicular lymphoma: comprehensive gene expression analysis whit insights into pathogenesis. Cancer Sci. 2014;105:608–615.
  • Liu Y, Hernandez AM, Shibata D, et al. BCL2 translocation frequency rises with age in humans. ProcNatlAcadSciUSA. 1994;91:8910–8914.
  • Bende RJ, Smit LA, Van Noesel CJ. Molecular pathways in follicular lymphoma. Leukemia. 2007;21:18.
  • Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311:1471.
  • Oviatt KL, Couser JB, Collins RD, et al. Malignant lymphomas of follicular center cell origin in humans. V. Incidence, clinical features and prognostic implications of transformation of small cleaved cell nodular lymphoma. Cancer. 1984;53:1109–1114.
  • Armitage JO, Dick FR, Corder MP. Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant. Cancer Treat Rep. 1981;65:413–418.
  • Qazi R, Aisenberg AC, Long JC. The natural history of nodular lymphoma. Cancer. 1976;37:1923–1927.
  • Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:5165–5169.
  • Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Geneva, Switzerland: World Health Organization; 2008.
  • De Jong D, Voetdijk BM, Beverstock GC, et al. Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med. 1988;318:1373–1378.
  • Gauwerky CE, Haluska FG, Tsujimoto Y, et al. Evolution of B-cell malignancy: pre-B-cell leukemia resulting from MYC activation in a B-cell neoplasm with a rearranged BCL2 gene. Proc Natl Acadsciusa. 1988;85:8548–8552.
  • Gall EA, Mallory TB. Malignant lymphoma: a clinico-pathologic survey of 618 cases. Am J Pathol. 1942;18:381–429.
  • Lossos IS. Higher-grade transformation of follicular lymphoma-a continuous enigma. Leukemia. 2005;19:1331–1333.
  • Lossos IS, Alizadeh AA, Diehn M, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-MYC and its regulated genes. Proc Natl Acadsci USA. 2002;99:8886–8891.
  • Do B, Lossos IS, Thorstenson Y, et al. Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma. Leuk Lymphoma. 2003;44:1317–1323.
  • Elenitoba-Johnson KS, Gascoyne RD, Lim MS, et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood. 1998;91:4677–4685.
  • Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clinoncol. 2007;25:290–298.
  • Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clinoncol. 2008;26:440–446.
  • De Jong D. Molecular patogénesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clinoncol. 2005;23:6358–6363.
  • Cerhan JR, Ansell SM, Fredericksen ZS, et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood. 2007;110:4455–4463.
  • Cerhan JR, Wang S, Mauer MJ, et al. Prognostic significance of host gene polymorphisms in follicular lymphoma. Blood. 2007;109:5439–5446.
  • Jong D, Boer JP. Predicting transformation in follicular lymphoma. Leuk Lymphoma. 2009;50:1406–1411.
  • Gine E, Montoto S, Bosch F, et al. The follicular lymphoma international prognostic index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol. 2006;17:1539–1545.
  • Al-Mansour M, Connors JM, Gascoyne RT, et al. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin’s lymphoma. J Clin Oncol. 2010;28:793–799.
  • Yuen AR, Kamel OW, Halpern J, et al. Long term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol. 1995;13:1726–1733.
  • Cullen MH, Lister TA, Brearley RI, et al. Histological transformation of non-Hodgkin’s lymphoma: a prospective study. Cancer. 1979;44:645–651.
  • Risdall R, Hoppe RT, Warnke R. Non-Hodgkin’s lymphoma: a study of the evolution of the disease based upon 92 autopsied cases. Cancer. 1979;44:529–542.
  • Garvin AJ, Simon RM, Osborne CK, et al. An autopsy study of histologic progression in non-Hodgkin’s lymphomas.192 cases from the National Cancer Institute. Cancer. 1983;52:393–398.
  • Ostrow SS, Diggs CH, Sutherlan JC, et al. Nodular poorly differentiated lymphocytic lymphoma: changes in histology and survival. Cancer Treat Rep. 1981;65:929–933.
  • Hubbard SM, Chabner BA, De Vita VT. Histologic progression in non-Hodgkin´s lymphoma. Blood. 1982;59:258–264.
  • Acker B, Hoppe RT, Colby TV, et al. Histologic conversion in the non-Hodgkin’s Lymphoma. J Clinoncol. 1983;1:11–16.
  • Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clinoncol. 1986;4:1470–1480.
  • Ersboll J, Schultz HB, Pedersen-Bjergaard J, et al. Follicular low-grade non-Hodgkin’s lymphoma: long-term outcome with or without tumor progression. Eur J Haematol. 1989;42(1):55–63.
  • Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors and outcome of lymphoma transformation in follicular lymphoma patients. J Clinoncol. 1997;15:1587–1594.
  • Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clinoncol. 2007;25:2426–2433.
  • Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol. 2012;157:188–196.
  • Link BK, Mauer M, Nowakowski G, et al. Rates and outcomes of follicular lymphoma transformation in the inmunochemotherapy era: a report from the university of iowa/mayo clinc specialized program of research excellence molecular epidemiology resource. J Clin Oncol. 2013;31:3272–3278.
  • Bains P, Al Tourah A, Campbell BA, et al. Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. Ann Oncol. 2013;24:428–432.
  • Wagner-Johnston N, Link B, Byrtek M, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the national lymphocare study (NLCS). Blood. 2015;126:851–857.
  • Sarkozy C, Trneny M, Xerri L, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34:2575–2582.
  • Lossos IS, Gascoyne RD. Transformation of follicular lymphoma. Best Pract Res Clinhaematol. 2011;24:135–146.
  • Haralambieva E, Boerma EJ, Van Imhoff GW, et al. Clinical immunophenotypic and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surgpathol. 2005;29:1652–1660.
  • Ning Y, Foss A, Kimball AS, et al. Characterization of a case of follicular lymphoma transformed into B-lymphoblastic leukemia. Mol Cytogent. 2013;6:34–40.
  • Xu X, Zhang L, Wang Y, et al. Doble-hit and triple hit lymphomas arising from follicular lymphoma following acquisition of MYC: report of two cases and literature review. Int J Clin Exp Pathol. 2013;6:788–794.
  • Pedersen MO, Gang AO, Poulsen TS, et al. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma- a single centre’s experience. Eur J Haematol. 2012;89:63–71.
  • Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-myc rearrangement. Haematologica. 2007;92:1335–1342.
  • Smeltzer J, Jones J, Ziesmer S, et al. Patterns of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. Clin Cancer Res. 2014;20:2862–2872.
  • Ruminy P, Jardin F, Picquenor JM, et al. S(mu) mutation patterns suggest different progression pathways in follicular lymphoma: early direct or late from FL progenitor cells. Blood. 2008;112:1951–1959.
  • Carlotti E, Wrench D, Matthews J, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood. 2009;113:3553–3557.
  • Eide MB, Liestol K, Lingjaerde OC, et al. Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood. 2010;116:1489–1497.
  • Okosun J, Bodor C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nature. 2014;46:176–181.
  • Martínez-Climent JA, Alizadeh A, Segraves R, et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood. 2003;101:3109–3117.
  • Davies AJ, Lee A, Taylor C, et al. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia. 2005;19:1459–1465.
  • Elenitoba-Johnson KS, Gascoyne RD, Lim M, et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood. 1998;91:4677–4685.
  • Lossos IS, Levy R. Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol. 2003;13:191–202.
  • Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 1993;82:1994–2004.
  • Capello D, Vitolo U, Pasqualucci L, et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood. 2000;95:651–659.
  • Davies AJ, Rosenwald G, Lee A, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol. 2006;136:286–293.
  • Hans SP, Weisenburger DD, Greiner TC, et al. Conformation of molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
  • Kridel R, Mottok A, Farinha P, et al. Cell of origin of transformed follicular lymphoma. Blood. 2015;126:2118–2127.
  • Brodtkorb M, Lingjaerde C, Huse K, et al. Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood. 2014;123(7):1051–1054.
  • Elenitoba-Johnson KS, Jenson SD, Abbott RT, et al. Involvement of multiple signalling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as target for therapy. Proc Natl Acadsci USA. 2003;100:7259–7264.
  • Blaker Y, Spetalen S, Brodtkorb M, et al. The tumour microenvironment influences survival and time to transformation in folicular lymphoma in the rituximab era. Br J Haematol. 2016. [Epub ahead of print]. DOI:10.1111/bjh.14201
  • Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of Follicular lymphoma transformation. Cell. 2014;6:130–140.
  • Baus D, Nonnenmacher F, Jankowski S, et al. STAT6 and STAT1 are essencial antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. Leukemia. 2009;23:1885–1893.
  • Kridel R, Chan FC, Mottok A, et al. Histological transformation and progression in follicular lymphoma: a clonal evolution study. PLOS One. 2016;13:e1002197.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.